Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

0
Player Avatar Fishboy1970 (< 20) Submitted: 6/23/2012 9:27:42 AM : Outperform Start Price: $1.27 ZLCS Score: -79.58

Just a hunch!

Featured Broker Partners


Advertisement